Printer Friendly
The Free Library
14,715,772 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Kyorin Pharmaceutical to Add New Item for Its Athlete's Foot Remedy Series.


Tokyo, Japan, Feb 23, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
) - Kyorin Pharmaceutical announced on February 22 that it will begin marketing TOE COOL Solution, a new item in its athlete's foot athlete's foot: see ringworm.
athlete's foot

Form of ringworm that affects the feet. In the inflammatory type, the infection may lie inactive much of the time, with occasional acute episodes in which blisters develop, mostly between the toes.
 remedy series TOE COOL, on March 1.

The new product, which contains amorolfine hydrochloride hydrochloride /hy·dro·chlo·ride/ (-klor´id) a salt of hydrochloric acid.

hy·dro·chlo·ride
n.
A compound resulting from the reaction of hydrochloric acid with an organic base.
 as an active ingredient, can exert beneficial effects with once-a-day dosage. One unit sells for 2,205 yen ($18.50).

Amorolfine hydrochloride is a switched OTC OTC

See: Over-the-counter.


OTC

See over-the-counter market (OTC).
 version of Pekiron Cream, Kyorin's proprietary ethical drug launched in February 2004.

The company aims to generate 200 million yen ($1.6 mil) in sales of the TOE COOL series in the first year.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Feb 24, 2006
Words:111
Previous Article:Kyowa Medex Releases Diagnostic Reagent for Type 3 Familial Hyperlipemia.
Next Article:AIST Develops PFOS Degradation Method.



Related Articles
ALLERGAN LICENSES QUINOLONE ANTIBIOTIC FROM KYORIN.
Aromatherapist's couch. (Books).(Brief Article)
OFFBEAT : `NONE OF THE ABOVE' A BIG FAN FAVORITE.(Sports)
Take care of our feet.(Brief Article)
Helpful herbal remedies for postpartum.(Postpartum)
20 best franchising opportunities: are you ready to own a proven business? Here's our list of the most promising franchises.(FRANCHISES)
Kyorin Pharmaceutical to License Its Overactive Bladder Drug to Korean LG Life Sciences.
Kyorin Pharmaceutical, Novartis AG Enter into Licensing Agreement for Immunosuppressant KRP-203.
Kyorin to Reorganize Its Group Businesses in October.
Two KVEA Emmys driven by mysteries and marathon man.(ENTERTAINMENT,KVEA, Corona, California (Television))(Brief article)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles